Vir looking ahead to other COVID settings after value-destroying miss in hospitalized patients

Vir and GSK are looking ahead to an imminent readout for their mAb to treat high-risk COVID-19 outpatients after a DSMB recommended the closure of a study arm evaluating the therapy in hospitalized patients.

Vir Biotechnology Inc. (NASDAQ:VIR) sank $15.96 (28%) to $41.78 on Wednesday, losing $2 billion in market cap, after revealing that although VIR-7831 met the criteria for advancing in the Phase II/III ACTIV-3 platform trial, concerns arose about the magnitude of its benefit in the hospitalized population...